TY - JOUR
T1 - Selection strategies for anticancer antibody discovery
T2 - Searching off the beaten path
AU - Sánchez-Martín, David
AU - Sørensen, Morten Dræby
AU - Lykkemark, Simon
AU - Sanz, Laura
AU - Kristensen, Peter
AU - Ruoslahti, Erkki
AU - Álvarez-Vallina, Luis
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Antibody-based drugs represent one of the most successful and promising therapeutic approaches in oncology. Large combinatorial phage antibody libraries are available for the identification of therapeutic antibodies and various technologies exist for their further conversion into multivalent and multispecific formats optimized for the desired pharmacokinetics and the pathological context. However, there is no technology for antigen profiling of intact tumors to identify tumor markers targetable with antibodies. Such constraints have led to a relative paucity of tumor-associated antigens for antibody targeting in oncology. Here we review novel approaches aimed at the identification of antibody-targetable, accessible antigens in intact tumors. We hope that such advanced selection approaches will be useful in the development of next-generation antibody therapies for cancer.
AB - Antibody-based drugs represent one of the most successful and promising therapeutic approaches in oncology. Large combinatorial phage antibody libraries are available for the identification of therapeutic antibodies and various technologies exist for their further conversion into multivalent and multispecific formats optimized for the desired pharmacokinetics and the pathological context. However, there is no technology for antigen profiling of intact tumors to identify tumor markers targetable with antibodies. Such constraints have led to a relative paucity of tumor-associated antigens for antibody targeting in oncology. Here we review novel approaches aimed at the identification of antibody-targetable, accessible antigens in intact tumors. We hope that such advanced selection approaches will be useful in the development of next-generation antibody therapies for cancer.
KW - Advanced phage selections
KW - Phage display
KW - Therapeutic antibodies
KW - Tumor-associated antigens
UR - http://www.scopus.com/inward/record.url?scp=84928049044&partnerID=8YFLogxK
U2 - 10.1016/j.tibtech.2015.02.008
DO - 10.1016/j.tibtech.2015.02.008
M3 - Review article
C2 - 25819764
AN - SCOPUS:84928049044
SN - 0167-7799
VL - 33
SP - 292
EP - 301
JO - Trends in Biotechnology
JF - Trends in Biotechnology
IS - 5
ER -